Cite
HARVARD Citation
Zahn, N. et al. (2019). MIDD0301 – A first‐in‐class anti‐inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression. Basic & clinical pharmacology & toxicology. 125 (1), pp. 75-84. [Online].